2nd Dec 2015 15:23
2 December 2015
Grant of Share Options
Clinigen Group plc (the "Company") (AIM: CLIN), announces that, on 30 November 2015, the following directors were granted share options, under the Clinigen Group Long Term Incentive Plan 2015, over a total of 159,354 ordinary shares of 0.1 pence each ("Ordinary Shares") as listed below. The options are nil cost options intended to vest on 30 November 2018, subject to the achievement of certain performance criteria.
Director | Number of share options granted | Total number of share options now held |
Martin Abell | 123,172 | 123,172 |
Shaun Chilton | 36,182 | 286,382 |
Contact Details
Clinigen Group plc |
Tel: +44 (0) 1283 495010 |
Peter George, Group Chief Executive Officer Shaun Chilton, Group Deputy CEO |
|
Martin Abell, Group Chief Financial Officer |
|
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade/Freddie Barnfield (Nominated Adviser) James Black/Tom Ballard (Corporate Broking) |
|
Peel Hunt LLP | Tel: +44 (0) 20 7418 8900 |
James Steel/Jock Maxwell Macdonald |
|
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell/Jayne Crook/Emma Barlow | Email: [email protected] |
Notes to Editors
About Clinigen Group
Clinigen Group is a global pharmaceutical and services company with a unique combination of businesses dedicated to delivering the right drug to the right patient at the right time.
The Group consists of four synergistic businesses that provide medicines to patients with unmet medical need; through Clinigen Clinical Trial Services we manage the supply of commercial medicines for clinical trials, through Idis Managed Access we run early access programs for our own and other companies' portfolios, our Idis Global Access team works directly with healthcare providers to enable ethical compliant access to unlicensed medicines, and through Clinigen Specialty Pharmaceuticals, we market our own portfolio of niche commercial products.
Clinigen is the global leader in clinical trial services and ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need. In October 2015, Clinigen acquired Link Healthcare, further strengthening our international distribution network in the AAA region - Asia, Africa and Australasia.
For more information, please visit www.clinigengroup.com
Related Shares:
CLIN.L